Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma

doi:10.3748/wjg.120320

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 39

This Article

(15)

(16)

(0)

(4)

(284)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Oct 21, 2026; 32(39): 120320
Published online Oct 21, 2026. doi: 10.3748/wjg.120320

Table 2 Hepatitis B virus reactivation incidence and clinical characteristics according to hepatitis B virus status, median (interquartile range)/n (%)

Characteristics	Chronic HBV¹, n = 727	Resolved HBV², n = 47	P value
Reactivation incidence	50 (6.9)	10 (21.3)	0.002
Clinical characteristics
Time to reactivation, months	12.5 (6.9-21.7)	11.5 (3.7-22.4)	0.820
Peak HBV DNA, log₁₀ IU/mL	5.3 (3.9-6.8)	1.5 (1.1-1.6)	< 0.001
Severity of reactivation
≥ 1 Log increase	47/50 (94.0)	7/10 (70.0)	0.052
Clinical outcome
All-cause mortality	29/50 (58.0)	5/10 (50.0)	0.733

P values were calculated using the Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables.

¹Hepatitis B surface antigen positive.

²Hepatitis B surface antigen negative, antibody to hepatitis B core antigen positive.

HBV: Hepatitis B virus.

Full Size Table

Citation: Kim DY, Jeong J, Hong JP, Lee JS, Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Kim DY, Lee HW. Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2026; 32(39): 120320
URL: https://www.wjgnet.com/1007-9327/full/v32/i39/120320.htm
DOI: https://dx.doi.org/10.3748/wjg.120320

Kim DY, Jeong J, Hong JP, Lee JS, Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Kim DY, Lee HW. Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2026; 32(39): 120320 [DOI: 10.3748/wjg.120320]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.